Royal London Asset Management LTD Genmab A/S Transaction History

Royal London Asset Management LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$25.13 - $30.27 $4.41 Million - $5.31 Million	-175,556 Reduced 77.88%	49,849 $1.25 Million
Q1 2024 May 14, 2024	SELL	$26.43 - $32.77 $43,583 - $54,037	-1,649 Reduced 0.73%	225,405 $6.74 Million
Q4 2023 Mar 01, 2024	BUY	$27.94 - $35.44 $5.71 Million - $7.24 Million	204,348 Added 899.97%	227,054 $7.23 Million
Q4 2023 Feb 13, 2024	SELL	$27.94 - $35.44 $6.45 Million - $8.18 Million	-230,799 Reduced 91.04%	22,706 $722,000
Q3 2023 Nov 14, 2023	BUY	$35.27 - $42.24 $8.94 Million - $10.7 Million	253,505 New	253,505 $8.94 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Royal London Asset Management LTD, based on Form 13F filings with the SEC.

Stay updated on Royal London Asset Management LTD with notifications on news.